Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Imaging

Therapeutic area intelligence for Imaging with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
3
Catalysts
0
Companies
1

Companies

Novartis →

Assets

Gadobutrol →
Oncology →
Zenara →

Recent signals(3)

RegulatoryJune 21, 2026

FDA Grants Approval for Gadobutrol ANDA219146 by Zenara

The FDA has granted approval for the ANDA219146 application for Gadobutrol submitted by Zenara.

CompetitiveJune 18, 2026

First-in-human study of NTSR1-targeted imaging in prostate cancer shows promise

[18F]-AlF-NOTA-neurotensin shows potential as an NTSR1-targeted radiotracer for prostate cancer imaging.

RegulatoryJune 18, 2026

FDA Grants Approval for Gadobutrol ANDA219287 by Viwit Pharm

The FDA has granted approval for the ANDA219287 application for Gadobutrol submitted by Viwit Pharm.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.